Phenotypes associated with this allele

• Allele Symbol: Tg(KLKB1-cre/ERT2)1Pcn
• Allele Name: transgene insertion 1, Pierre Chambon
• Allele ID: MGI:3775927
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Ar^tm3.1(AR)Ska/Y Tg(KLKB1-cre/ERT2)1Pcn/0	involves: C57BL/6 * C57BL/6J * CBA	MGI:4946829
cn2	Ar^tm3.1(AR)Ska/Y Tg(KLKB1-cre/ERT2)1Pcn/0 Tg(TRAMP)8247Ng/0	involves: C57BL/6 * C57BL/6J * CBA	MGI:4946830

Genotype
MGI:4946829

cn1

• Allelic Composition: Ar^tm3.1(AR)Ska/Y; Tg(KLKB1-cre/ERT2)1Pcn/0
• Genetic Background: involves: C57BL/6 * C57BL/6J * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

reproductive system

increased prostate gland ventral lobe weight ( J:170092 )

♂ • at 16 weeks, tamoxifen-treated mice exhibit increased ventral prostate weight compared with Ar^tm3.1(AR)Ska hemizygous males

increased prostate gland weight ( J:170092 )

♂ • at 16 weeks, tamoxifen-treated mice exhibit increased total prostate weight compared with Ar^tm3.1(AR)Ska hemizygous males

abnormal prostate gland physiology ( J:170092 )

♂ • tamoxifen-treated mice exhibit increased proliferation of prostate cells compared to in Ar^tm3.1(AR)Ska hemizygous males

♂ • tamoxifen-treated mice exhibit increased growth in response to androgen antagonist and estrogen unlike Ar^tm3.1(AR)Ska hemizygous males

reduced fertility ( J:170092 )

♂ • tamoxifen-treated male mice exhibit reduced reproductive activity compared with wild-type mice

homeostasis/metabolism

increased circulating testosterone level ( J:170092 )

♂ • in tamoxifen-treated male mice

endocrine/exocrine glands

increased prostate gland ventral lobe weight ( J:170092 )

♂ • at 16 weeks, tamoxifen-treated mice exhibit increased ventral prostate weight compared with Ar^tm3.1(AR)Ska hemizygous males

increased prostate gland weight ( J:170092 )

♂ • at 16 weeks, tamoxifen-treated mice exhibit increased total prostate weight compared with Ar^tm3.1(AR)Ska hemizygous males

abnormal prostate gland physiology ( J:170092 )

♂ • tamoxifen-treated mice exhibit increased proliferation of prostate cells compared to in Ar^tm3.1(AR)Ska hemizygous males

♂ • tamoxifen-treated mice exhibit increased growth in response to androgen antagonist and estrogen unlike Ar^tm3.1(AR)Ska hemizygous males

Genotype
MGI:4946830

cn2

• Allelic Composition: Ar^tm3.1(AR)Ska/Y; Tg(KLKB1-cre/ERT2)1Pcn/0; Tg(TRAMP)8247Ng/0
• Genetic Background: involves: C57BL/6 * C57BL/6J * CBA

mortality/aging

premature death ( J:170092 )

♂ • tamoxifen-treated mice die at around 36 weeks of age compared with 48 weeks for Ar^tm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males

neoplasm

increased prostate gland tumor incidence ( J:170092 )

♂ • tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Ar^tm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males

abnormal tumor morphology ( J:170092 )

♂ • castration of nude mice transplanted with tumors from tamoxifen-treated mice attenuates tumor growth more than in Ar^tm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males

increased tumor growth/size ( J:170092 )

♂ • prostate tumors from tamoxifen-treated mice transplanted into nude mice exhibit increased tumor growth compared with tumors from Ar^tm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males

decreased tumor latency ( J:170092 )

♂ • tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Ar^tm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males

reproductive system

increased prostate gland tumor incidence ( J:170092 )

♂ • tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Ar^tm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:170092 )

♂ • tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Ar^tm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males